TMC435-TiDP16-C112 - Interaction Trial With Antidepressants
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of steady-state concentrations of
TMC435 150mg q.d. (once a day) on the steady-state pharmacokinetics of escitalopram 10 mg
q.d., and vice versa. Steady state is a term which means that the drug has been given long
enough so that the plasma concentrations will remain the same with each subsequent dose.
TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection.
Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream, distributed in the
body and eliminated from the body.